Celldex Therapeutics (NASDAQ:CLDX) is one of today's biggest movers, up 4.0% to $19.40. The Dow Jones Industrial Average is now trading fractionally higher to 14,996 and the S&P is trading 0.2% higher to 1,618.
Celldex Therapeutics Inc., a biopharmaceutical company, uses applications of immunology to prevent and treat diseases. The Company's products treat autoimmune diseases, cardiovascular diseases, cancer, and inflammation, as well as infectious diseases and organ transplant rejection.
Celldex Therapeutics share prices have moved between a 52-week high of $19.50 and a 52-week low of $4.46 and are now trading 335% above that low price at $19.40 per share. In the last five trading sessions, the 50-day moving average (MA) has climbed 2.0% while the 200-day MA has risen 2.0%.
Based on a current price of $19.40, Celldex Therapeutics is currently 18.4% above its average consensus analyst price target of $15.83. Celldex Therapeutics shares have support at the 50-day moving average (MA) of $13.84 and additional support at the 200-day MA of $9.38.